PeproMene Bio Announces Breakthrough Phase 1 Clinical Trial Results for BAFF-R CAR T-cell Therapy in Relapsed/Refractory B-cell Lymphomas Published in The Lancet

PeproMene Bio, Inc. announced the publication of Phase 1 clinical trial results in The Lancet, demonstrating deep and durable complete responses in patients with relapsed or refractory B-cell lymphomas, including those who previously failed CD19 CAR T-cell therapy. This research offers a new therapeutic target and a new chance for patients whose lymphoma returns.